Good day everyone and welcome to today’s CBOE Holdings First Quarter 2012 Earnings Conference Call. At this time, all lines are in a listen-only mode. Later we’ll conduct a question and answer session and instructions will be given at that time. (Operator Instructions). At this time for opening introduction, I’d like to turn the call over to Debbie Koopman, Vice President of Investor Relations. Please begin.

Thank you. Good afternoon and thank you for joining us on our first quarter conference call. On the call today, Bill Brodsky, our Chairman and CEO, will discuss the quarter and our strategic initiative for 2012, then Alan Dean, our Executive Vice President and CFO will detail our first quarter 2012 financial results. Following their comments, we will open the call to Q&A. Also, joining us for Q&A is our President and COO, Ed Tilly; and our Executive Vice President and Chief Business Development Officer, Ed Provost. In addition, I’d like to point out that this presentation will include the use of several slides. We will be showing the slides and providing commentary on each. A downloadable copy of the slide presentation is available on the Investor Relations portion of our website. As a preliminary note, you should be aware, that this presentation contains forward-looking statements, which represent our current judgment on what the future may hold, and while we believe these judgments are reasonable, these forward-looking statements are not guarantees of future performance and involve certain assumptions, risks and uncertainties. Actual outcomes and results may differ materially from what is expressed or implied in any forward-looking statements. Please refer to our filings with the SEC for a full discussion of the factors that may affect any forward-looking statements. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, after this conference call. Now, I’d like to turn the call over to Bill Brodsky.

Thank you, Debbie, and good afternoon. Thanks for joining us. I’m pleased to report that fiscal year 2012 began with another strong quarter at CBOE Holdings. We delivered our seventh consecutive quarter of year-over-year earnings per share growth on an adjusted basis, as well as significant gains in market share. Moreover, we achieved solid financial results, despite lower industry-wide trading volumes by prudently managing expenses, while investing in future growth. Our company’s mission is to create value for stockholders by generating industry-leading profit margins and growth rates who will diversify portfolio of risk management products and services. It is our mission to operate as a sub-regulatory organization with the highest integrity and confidence and to create an effective compliance in regulatory structure that functions as a trusted financial institution that provides all market participants and investors for the market price is reliable, efficient, and fair. We issued annual 10-K filing disclosed with the Securities and Exchange Commission as investigating CBOE’s compliance with its obligation to the sub regulatory organizations. And the CBOE is simultaneously conducting its own review of its compliance. We are unable to comment on the SEC’s investigation except to say that we continue to cooperate. We have conducted a rigorous self-examination of practice throughout our exchanges and we’re sharing the results of that review with the SEC. In the past two years CBOE has navigated significant shift in our business and our ownership model. Our self-examination is an exhaustive inventory of all of our processes and practices to ensure that the highest ethical standards are embedded in every aspect of our current operation. This past quarter we instituted company-wide educational seminars, the detail have the requirements of the SEC and our own rules applied to CBOE as well as, as an SRO. We have also begun to…

Thank you, Bill, and good afternoon, everyone. As Bill mentioned, we delivered solid first quarter results despite lower trading volume, industry wise. Our ability to delve our bottom line consistently even in challenging market conditions highlight the underlying strength of our products offerings and are focused on managing costs while investing in long-term growth. Adjusted net income allocated to common stockholders were $33 million up 2% from one year ago. Adjusted diluted earnings per share has reached 3% from one year ago to $0.37. While operating revenues of $121.4 million declined 2% from one year ago, adjusted operating expenses were down 3% and adjusted operating margins increased by 80 basis points to 47.5%. Before I continue, let me point out that our GAAP results reported for the first quarter of 2012 and 2011 include certain unusual items that impact the comparison of our operating performance. These items are detailed in our non-GAAP information provided in the press release and in the appendix of our slide back. To gain a better understanding of the key drivers during the quarter, let me begin with the operating revenues. As shown on this slide, operating revenues decreased by $2.6 million or 2% in the first quarter from one year ago. The decrease reflects declines in transaction fees and access fees offset significantly by strong growth in exchange services and other fees and market data fees. Bill (inaudible) January 3, fee changes which included the introduction of a new volume of incentive program and revamping our liquidity provider sliding fee scale to exclude our proprietary products. These changes were designed to drive incremental volume to our exchanges, leverage the strength of our proprietary products and maintain competitive pricing across all of our service areas. We realized significant gains in market share as a result of…

At this time we will be happy to take questions. We will ask that you limit your questions to one per person to allow time to get to everyone, feel free to get back in the queue and if time permits we will take a second question.

(Operator Instructions). Our first question comes from Richard Repetto with Sandler O’Neill. Please go ahead with your question. Richard Repetto – Sandler O’Neill: Yeah, hi, Bill and Alan, and Ed and Tilly. I guess the question is you did make some aggressive moves with the volume incentive program and you’re seeing some market share shifts, but you are seeing some RPC declines as well. And I was wondering have we done the analysis or how would you evaluate the overall changes, was it beneficial we’re going through the numbers now, but how did you look at it as versus if you would have maintained just the same market share the same RPC last quarter.

Yeah, hi, Rich. This is, Alan, yeah, there are so many moving parts that you have to look at doing that analysis such as product mix, pricing changes made during the quarter, changes unusual behavior as well as market conditions. You just can’t look at transaction fees as you alluded to, you have to look at the entire picture including market data fees, which are significantly up this quarter, trading volume incentive expenses, which as you saw are down, because of the changes we made during the quarter, and those changes were made possible by the increased market share coming from VIP. Demand from trading permit holders continues to stay strong and I believe that VIP was somewhat responsible for that. Exchange services and other fees another line item that was up significantly this quarter, turned out to be really good, better than the guidance that we provided. And again I believe that VIP was helpful in allowing us to maintain the demand in that revenue line item. And finally, the additional market share certainly added to our liquidity enhancing the quality of our markets, which helps a lot of things. So overall I feel that CBOE financially benefited from VIP and increase in the market share that resulted. Richard Repetto – Sandler O’Neill: Great, thank you.

Our next question comes from Alex Kramm with UBS. Please go ahead with your questions. Alexander Kramm – UBS: Hey good evening. Maybe just saying what Rich said here on the – I guess VIP experiments I think you’ve said on the prepared remarks, you made some changes following the original program. So can you just talk us a little bit how should be thinking about RPCs and overall revenue in line of those changes? Thank you.

This is Alan; we did make some changes, even recently, effective today that we made another change in the VIP program. I think you should look at our revenue per contract similar to the way I tried to frame it, after our fourth quarter earnings call, which is that – more market share would probably result in a declining RPC for equity options and maybe ETF options, which is a good thing because you see so many other line items are positively affected by that. And if you saw market share hold steady then I think it would be reasonable to assume that RPC also would hold steady and the (inaudible) classes specifically equity options and ETF options. Alexander Kramm – UBS: All right, thanks.

Our next question comes from Jillian Miller with BMO Capital Markets. Please go ahead with your question. Jillian Miller – BMO Capital Markets: Thanks guys. Before getting towards the end of your buyback authorization, just wondering, the intent is going forward is a further authorization something you’ve already been in dialog with the board about – and I guess there is more generally, how you’re thinking about capital returns strategy going forward because they are building out some cash in the balance sheet maybe if you can give us a sense for whether you’d be more likely to raise the dividend or increase fee buyback pays with excess capital? Thanks.

Yes, Alan Dean again. Let me first remind you that since our IPO barely two years ago and this was in my prepared remarks. We have returned over $565 million to our shareholders to stack repurchases, buybacks, dividends. And our policy hasn’t changed the policy of the board. First we look to reinvest in our business and after that we’ll look to return all excess capital to our shareholders to enhance the long-term return in the value of their holdings in CBOE. Now as far as our current stock repurchase program all I can say at this point is that we intend to continue, complete the problem and just as we were before, we intend to be opportunistic on how we do that. Jillian Miller – BMO Capital Markets: Okay, thank you.

Our next question comes from Michael Carrier with Deutsche Bank. Please go ahead with your question. Michael Carrier – Deutsche Bank: Thanks guys. Maybe just a question on expenses, it looks like, the run rate as far has been on the low end or even better, in low end of the guidance for the full year. So, I guess first is there somebody’s new initiatives that you discussed, at the beginning to some of these kick in and so we would expect the expense run rate to start the ramp up, or is it maybe just more likely to be at the lower end of that guidance range?

Alan Dean again, if you take our core expenses for the quarter and multiple then by them by four certainly, we are under our – the annual guidance that we gave you. However, if you take the same core operating expenses for the quarter and compare them to the core expenses for the first quarter of last year, they are actually up 3%, which is a lot closer in line with the guidance that we gave to you three months ago, which is an increase of 4% to 7% over the last year. And also, I do expect some expenses to ramp up as we go through the year. So consequently, we’re maintaining in our expense guidance of $173 million to $178 million for 2012 and that does represent a 47% increase over 2011, which all by itself was kind of depressed because we did – we were tight with our expense recall, expense control last year. Michael Carrier – Deutsche Bank: Okay, thanks a lot.

Our next question comes from Nim Alexander with KBW. Please go ahead with your question. Niamh Alexander – KBW: Hi, thanks for taking my question. On the technology initiatives and is there ways to quantity maybe the spend, or is it most of the spends behind you kind of in the CapEx. And then what is the revenue opportunity from this are maybe new co-location fees, that you could start charging is there – is it maybe higher volume from improved latency. Could you expand a little bit more on that?

Alan Dean again. The cost of CBOE command, mostly the move out to the East Coast and the functionality changes like CFLEX 2.0, they are all included within the guidance that we gave you both CapEx and our core operating expenses. We are breaking them of any further than that at this point in time. The co-location revenue that is in that line item exchange services and other fees and co-location is one of the items that one of the fee increases that we put in at the beginning of this year and has included in that line item and partially accounts for the increase in that revenue. So beyond what we’ve already done, I don’t think I could count on anymore incremental revenue from co-location because of CBOE command, the changes that we’re making to the functionality or to move out to the East Coast.

(inaudible) what Alan saying, this Bill Brodsky, this initiative gives us additional flexibility, it does reduce the latency and it gives us tremendous advantages in terms of anything that relate to over-the-counter initiative. So it really is following through on initiatives that we had established, but the CFLEX 2.0 is something that we believe is quite significant. Niamh Alexander – KBW: Okay. Thanks.

Our next question comes from Howard Chen of Credit Suisse. Please go ahead with your question. Howard Chen – Credit Suisse: Alan, I wanted to follow-up on your comments on the exchange fees, on that you could see some delayed impact from clients. Does that mean clients what actually have to come in pull additional lines and have you seen any of that post adjusting the fee schedules on the recent months?

We have seen some pullback early on, if sometimes the reaction is not immediate and it is in pulling lines, it could be something as simple as reducing their logins that you have with the CBOE command or trade engine. So, it’s a fairly easy thing to do, but you don’t want to do it in an environment where volume or market share is growing and volume is there. And so, I really do believe that VIP and the increase in the market share helped mitigate the lost of the bleeding (inaudible). Howard Chen – Credit Suisse: Okay, thanks. I mean just a quick clarification, and Alan on your commentary about, is it more based on conservatism or do you see like a pipeline of people who are collapsing log-ins and doing things like that?

At this point in time, no, I don’t see a line of people looking to get out or dramatically change what they are doing, but even one or two large users making a large move could dramatically impact this line items. And so it wouldn’t be prudent for me to count on that revenue for the remainder of the year given that we are still so early in the year. Howard Chen – Credit Suisse: It makes sense. Thanks a lot, Al.

Your next question comes from Patrick O’Shaughnessy with Raymond James. Please go ahead with your question. Patrick O’Shaughnessy – Raymond James: Hey, good afternoon.

Hey, Pat, how are you? Patrick O’Shaughnessy – Raymond James: Good, good. So the – your volatility franchise is obviously very important to you. How careful do you guys have to be or how much do you monitor the indexes that are tied to the VIX, obviously, there is a well published kind of disconnect this past quarter between, I think of the three VIX and the underlying VIX and how much do you worry about the harming the brand of your volatility franchise?

This Will Brodsky. I think what’s before I can hear is that, the index that you’ve talked about really related to the use of leverage on the ETF. And I think what – the most important area is customer education, and the unique feature of leverage products, but from what we can see it appears the issuer who had the problem has addressed it, and it was a unique situation and didn’t have any connection to any of the other 45 ETPs that are currently tied to our VIX. Patrick O’Shaughnessy – Raymond James: Thank you.

Our next question comes from Dan Fannon with Jefferies. Please go ahead with your question. Daniel Fannon – Jefferies: Hi, good afternoon. I guess if you could just discuss kind of the competitive framework generally in the options market today and kind of how you see the potentially intensifying as the year progresses and then with that as you’ve been kind of tweaking prices all we have still to date is that something we should expect you know continue based on the changes in volume?

This is Will Brodsky. I will take the first crack at this. We operate in my view in the most competitive segments of exchange markets in the United States. And as a result, it is very dynamic and it is a day by day competition, so we monitor this daily and we will continue to do it. And it is the way we are operating and happily I think we’ve done pretty as well.

The next question comes from Justin Schack with Rosenblatt Securities. Please go ahead with your question. Justin Schack – Rosenblatt Securities: Hi, I’ll start the question on may be different angle on the best question that Patrick asked. Can you guys breakdown how much of the VIX options for the futures volume comes from or it’s related to you PTPs based on that. How I know you partially answered this when Patrick asked, but how are going about, I think it was the public size the regulator, regulators are looking at what happens with (inaudible) some speculation about the potential changes to you the structure of that market and respected relations and redemptions and what’s that could have over long-term on that volume that we getting those ETPs.

One of things, this is Bill again and one of things I said earlier is that there continues to growth in not only in the products, but the assets under management in these exchange traded products. And there is no doubt that as more assets are deployed in to different products, there is a clear correlation between the amount of products, the assets under management and the volume that we are seeing particularly in the VIX futures. It is just a natural thing, they’re going to balance off every day and we look that as very constructive. But I just go back to what I’ve said earlier and that is that there are unique features to leverage products that need not to be related to VIX there are other leveraged exchange traded products out there I think what is very important is that people need to understand about the suitability issue and they’re not designed for buy and hold investors, these are unique tactical instruments. Justin Schack – Rosenblatt Securities: Okay, thanks Bill.

Your next question comes from Ken Worthington of JP Morgan. Please go ahead with your question. Kenneth Worthington – JP Morgan: Hi good evening. Just (inaudible) to VIP program a little bit more finally. You’ve obviously made some changes and there is a reasonably big reaction in terms of market share, you’re on the winning side, others are on the losing side. Why don’t you think we’ve seen bigger pricing changes, priced some of your competitors to try to neutralize the benefit that you’ve seen thus far, or is it you have been making so many moves that can’t quite catch up and if you look out six months I know Bill you said you are in the one of the most competitive markets, but to what extent our concerns about the stadium scenario where everybody stands up and no one can see a apply pricing here?

This is Alan Dean, I think that we are in a unique position in the options industry, different from anyone else because of our proprietary products. And the SPX and VIX specifically. And having those two products allows us flexibility, I think it gives us a competitive advantage that others don’t have. So there could be a reason why others have not responded as aggressively, Ed Tilly do you have anything?

Yeah, I think as we stated when we announced the VIP program early on the beginning in the year that we concentrated on a very largest consolidators of liquidity. And I think the immediate response that we are seeing most active is Philadelphia trying to go after the smaller consolidator. And with that obviously, the impact on share will be different, but it’s a different targeted market. It actually circles back to a couple of questions earlier, when we continue to see pricing tweaks, we will see, we will continue to change its pricing. Of course, it’s what we do and we look at the competitive landscape and the changes even in VIP month in, month out as from our entire team that’s what these guys do. So I think we will see changes going forward, we’ve seen Philadelphia change, CBOE will continue to change. We will look to see to and continue to change, this is part of the business and we will continue to do that moving forward. Kenneth Worthington – JP Morgan: Thank you.

Your next question comes from Chris Allen of Evercore. Please go ahead with your question. Christopher Allen – Evercore: Good afternoon, guys.

Good afternoon, Chris.

Hi. Christopher Allen – Evercore: I might have missed this, but can you just give us a little more color just to what’s driving incremental increase and expenses moving forward. And you’ve already made some hires to address some of the SEC related issues, it looks like are there more – you said there is going to be more to come, or have you all been spending on some of the seminars and kind of what else we drive – expect to drive moving forward?

Well, the – let me go back to the analysis that I cannot – that I laid out and when I answered the question before. If you compare the first quarter core operating expenses of 2012, compared to the first quarter of 2011, we are up 3%. And I expect that our expenses will grow during the year even if we don’t complete our move out to the East Coast. Even if we don’t continue to enhance CBOE Command, and when you add all those things into the natural growth rate of expenses, that’s why I believe that to expect an increase in expenses of 4% in 2012 at a minimum of over 2011 is a reasonable thing to expect. Christopher Allen – Evercore: Good. Thanks, guys.

Your next question comes from Justin Cressall with Morningstar Equity. Please go ahead with your question. Gaston Ceron – Morningstar Equity: Hi, good afternoon, it’s Gaston Ceron with Morningstar Equity Research. Thanks for taking my question. Just a real quick, Bill I wanted to go back to something you’ve said, got to believe the sort of – I actually I am not sort of the call, and I might have heard all of that you said. But I think you’re addressing some of these recent regulatory issues that are out there, and I thought you said something about possibly higher kind of expenses going forward on the regulatory front, I’m curious if you have at this early stage sort of any sort of estimate of what the current run rate impact of that might be or what we should we expect sort of a modeling – for a modeling purpose for by the way cost going forward?

Yeah, actually I didn’t address any expenses in that regard, but Alan just did, but I will ask him to just kind of reiterate what he just said. Alan? Gaston Ceron – Morningstar Equity: I’m sorry, I’m also missed that, I apologize.

That’s okay Gaston. What I said is that, the expenses related to CFLEX related to moving out to the East Coast any other functional enhancements that we make to our trade engine CBOE Command related to regulatory enhancements, that’s all included in our guidance and not incremental and that’s why we see the year right now. And we are being specific about what each of those items costs. Gaston Ceron – Morningstar Equity: All right. And anything that might come from any conversation we have regulators that’s not something or especially commenting on right now or?

Well, certainly we are not commenting on conversations with regulators, but I’m quite frankly, I look at the whole regulatory matters an opportunity to just to take a fresh look at things. As I said in my prepared remarks, we’ve gone through dramatic changes in our whole operations in the last three to five years. And this is an opportunity to take a fresh look in the environment we are in and just do things that we think are right to do. But as Alan said, we think we can do this within the contract that the expense guidance in given. Gaston Ceron – Morningstar Equity: Understood. Thank you very much.

Our next question comes from Matthew Heinz with Stifel Nicolaus. Please go ahead with your questions. Matthew Heinz – Stifel Nicolaus: Hi, Good afternoon.

Hi, Heinz. Matthew Heinz – Stifel Nicolaus: So we’re continuing to see kind of a broad market shift towards ETF products, I guess TY and IWM relative to from your higher margin index products. Just incremental share gains, but I’m wondering and how you are thinking about that trend and whether you view those products as a competitive threat or nearly just kind of complimentary to your index product suite?

Yeah. Well, I’m not sure I either understand or agree with your permits. The market will choose products based on what’s going on when markets are not as volatile, they go to indexes when it’s more volatile, they may go to individual stocks. But that certainly now – what we’re seeing now, I mean you look at our VIX product lines and there is dramatic growth there, which have nothing to do with what’s going on in IWM or other things. And the other thing that we’re seeing is the increased growth in our XPS line which is really attributable to whole variety of things the weeklies the fact that as VIX grows there is more volume in SPX. And this is a whole host of things that are different and as more business is done by institutions we’re going to see more business in SPX. So I think these are kind of very unique products that are not necessarily related to what I’ll call broader customer interest in traditional ETFs or individual equity options. Matthew Heinz – Stifel Nicolaus: Okay, let’s stripping out the VIX and just how looking apples-to-apples that SPX versus FTY I mean do you think that in terms of contract count you think that’s attributable to less institutional activity?

Just remember that the SPX is 10 times the size of the spider and I looked at the open interest from April to – from March to April. And the decline overall in SPY and open interest with dramatically greater than the decline in SPX, I think it was 4% decline in open interest in SPX versus 16% decline in SPY. So these are numbers that we watched very carefully and I just think that you got to look at them and try to make your own analysis. Matthew Heinz – Stifel Nicolaus: Okay. I appreciate that. Thank you.

Our next question comes from Ed Ditmire with Macquarie. Please go ahead with your question. Edward Ditmire – Macquarie: Most my questions has been answered, but just I had a quick housekeeping and can you tell us how much of the long LTIP award component is embedded in the comp expense in the quarter?

Yeah, I think it’s in the press release. And don’t get it pull that out.

2.7.

Debby has got correct answer (inaudible).

2.7 million. Edward Ditmire – Macquarie: Okay.

The $3.7 million. Edward Ditmire – Macquarie: Okay, thank you.

Our next question comes from Roger Freeman with Barclays Capital. Please go ahead with your questions. Roger Freeman – Barclays Capital: Hi, good evening.

Hey, Roger. Roger Freeman – Barclays Capital: Hi. Yes on SPX scale I know you’ve talked about this in the past in the last quarter about just being a sort of a long term build. I think last quarter you said you hired sales person to which for the New York area they try promote the usage of it, can you just talk to maybe what feedback has been and what where it hasn’t – haven’t made the penetration here I yet or where you’re thinking up further tailoring in the selling efforts to drive penetration on it.

Hi, Roger Ed Provo. Roger Freeman – Barclays Capital: Hi.

So we have brought on the physicians that we described in the last earnings call everybody’s on board both in the New York office and in Chicago our program is not materially changed from what we have been doing since we launched the product, primary focus being active, retail, and the hedge fund community one of the people we brought in is very much in the hedge fund side of the business has tremendously strong contacts in that community and we have dialogue everyday with both current and prospective users of the product. We remain very optimistic that this product will begin to pickup volume, the users, and the people who are looking at it with the product makes sense, it works, it’s distinguishable from our SPX products and they like the market model. So we’re very committed to staying on the same path that we’ve been on.

And let me add a little bit further, Roger, just to clarify, Ed hired that additional person not specifically for SPXpm, we are selling the complex and pushing our institutions into SPX whether it’s the traditional four base the weekly contracts that has enjoyed terrific growth with the PM. So we are, as far as to say we can go as far say we are agnostic as to what our institutional users pick up from that sales effort and we are just trying to drive everything back into their propitiatory complex.

Just to add one more point to add in Ed’s comments and I think Bill touched on it, in his opening comments. One of the things we’ve been very encouraged is the steady growth in open interest and at expiration in both March and April it did exceed a hundred thousand contracts again those are adjusted equal to a million spider contracts and we are optimistic if trend is going to continue along with average daily volume. So again we couldn’t be more optimistic, but it is a long term process and much away we thought it would play out. Roger Freeman – Barclays Capital: Okay. Thank you.

Our next question comes from Jillian Miller with BMO Capital Markets. Please go ahead with your question. Jillian Miller – BMO Capital Markets: Thanks. So even the volatility haven’t been particularly high end February or March, the VIX complex is doing really well and I know that on the futures side, a lot of that’s kind of driven by the mixed incentive products. And on the option side is that also the case or there is something else that’s been driving that?

I think it has to do with the – there is still the volatility space being very much at its infancy. And so volatile, low volatility environment we have lots of people who are analyzing the product coming to our seminars, learning about how volatility works and becoming new users of the products. So that while if we saw some spec of volatility, with no doubt see an increase in volume, where we are looking at as growing the user base and in these low volatility environment these people have a lot of opportunity to focus on products like VIX that they might not be able to focus on., if there was a much more active market. I would note also that we saw a great evidence of this at our – I think with our 26th Annual Risk Management Conference in Florida, which we held in March, we had 300 buy-side institutional portfolio managers, many of them were very much concentrated in the educational seminars focused on the VIX products. So again, in this particular product, we just have a tremendous growth in the rate of new users of the product. Jillian Miller – BMO Capital Markets: Okay, and that’s helpful. And then just quickly has there been any update on the OCC, I guess SEC approval for the clearing on the OTC, S&P options, have they gotten – I think what’s kind of the – your thought on timeline there?

This is Ed Tilly. We have not seen approval, we do expect approval – the only indication we can get is when OCC shares these things with us, so I would push that out certainly, not expecting that immediately, but maybe at the end of the quarter or early next quarter. Again, really the information will be maybe much more public by OCC, but we are learning is that there is interest and that’s really exciting and encouraging to us, especially when we can look at a multipronged approach at moving OTC business to centrally cleared, to centrally – to being centrally cleared. And this complement CBOE’s effort in our CFLEX 2.0, so that we can go out, Ed Provost team can go out and offer more than one alternative to OTC trading. So it really works quite well with our timing and launching CFLEX 2.0 in the OCC’s approval, pending approval to come directly to clearing. So it’s just a great opportunity for us to sell the opportunity. Jillian Miller – BMO Capital Markets: Thank you.

Our first next question comes from Matthew Heinz of Stifel Nicolaus. Please go ahead with your question. Matthew Heinz – Stifel Nicolaus: Hi, just a quick follow-up on the access fees, it looks like that the annualized 1Q rate is tracking slightly below the midpoint of your previous guidance? Just wondering if there are any changes there or is everything remaining the same what would the drivers be to it is kind of getting cut off?

Yeah, it just tracking just a fair below the low side of our guidance. And we haven’t seen any declines in demand and we feel like that the guidance that we gave you is still important still relevant and appropriate. So we are maintaining that for the rest of the year. Matthew Heinz – Stifel Nicolaus: Okay, thank you.

I’m not showing any other questions in the queue. I’d like to turn it back over for closing comments. Please

Thank you all for joining us today and thank you for your interest in CBOE.